Literature DB >> 6120945

Renin classification for diuretic and beta-blocker treatment of black hypertensive patients.

O B Holland, C Fairchild.   

Abstract

Renin classification has been proposed to guide initial treatment of hypertensive patients with diuretics vs beta-blockers. Most previous studies evaluating this issue have utilized patient populations that were white or predominantly white. Black hypertensives have been noted to differ from white hypertensives in several respects. To evaluate the clinical utility of renin classification in black hypertensives, we compared the blood pressure response of low vs normal renin patients during double-blind treatment with either hydrochlorothiazide or beta blocker (metoprolol or oxprenolol). Hydrochlorothiazide a significantly (P less than 0.05-0.01) larger blood pressure fall than beta-blocker, though there was no difference in the response of low vs normal renin patients. Thus, renin classification does not appear to guide initial selection of diuretic vs beta blocker therapy of black hypertensives, and diuretic therapy is more effective.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120945     DOI: 10.1016/0021-9681(82)90138-2

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  3 in total

Review 1.  The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks.

Authors:  J R M'Buyamba-Kabangu; M Tambwe
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

2.  Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Authors:  Mai Mehanna; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-21       Impact factor: 3.738

Review 3.  Metoprolol succinate extended release/hydrochlorothiazide combination tablets.

Authors:  James W Hainer; Jennifer Sugg
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.